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Abstract: Heterogeneous nuclear ribonucleoprotein (HNRNP) A1 and A2 are the most abundant HNRNPs with nearly identical
functions, and play important roles in regulating gene expression at multiple levels (i.e. transcription, posttranscription, and translation).
However, the expression and regulation mechanism of HNRNPA1 and A2 themselves remain unclear. In this study, the amino acid
sequences of HNRNPA1 and HNRNPA2 were compared and found to have 78% and 86% homology in key functional domains.
Transfection of HEK293 cells with small interfering RNA and overexpression vectors of HNRNPA1 and HNRNPA2 demonstrated that
HNRNPA1 and HNRNPA2 paralogs regulate each other’s expression in a compensatory manner at both the RNA and protein levels.
Multiprimer reverse transcription-polymerase chain reaction showed that HNRNPA1 and HNRNPA2 did not affect splicing of the
HNRNPA2 and HNRNPA1 gene. Using luciferase reporting system, we found that compensatory degradation was mediated by the
3′UTR of the two genes rather than by the promoter. Moreover, treatment with cycloheximide inhibited the compensatory regulation.
Our results indicate a novel regulation mechanism of HNRNPA1 and A2 expression. Through compensatory regulation, the expression
levels of HNRNPA1 and HNRNPA2 are strictly controlled within a certain range to maintain normal cellular activities under different
physiological conditions.
Key words: HNRNPA1, HNRNPA2, posttranscriptional gene regulation, 3′UTR, alternative splicing

1. Introduction
Heterogeneous nuclear ribonucleoprotein A1 (HNRNPA1,
also known as UP1) and HNRNPA2 (also known as
A2B1), encoded by different genes, are among the most
abundant RNA-binding proteins and nucleoplasm shuttle
proteins. Both HNRNPA1 and HNRNPA2 can produce
multiple transcripts through alternative splicing. Fulllength HNRNPA1 contains 11 exons and encodes 372
amino acids (HNRNPA1b, 38 kDa), whereas a shortened
transcript produced by exon 7b skipping contains 320
amino acids (lacking amino acids 253–303; HNRNPA1a,
34 kDa). Full-length HNRNPA2 contains 12 exons, and
produces four proteins due to alternative splicing of exon
2 and exon 9, which contain HNRNPB1 (353 amino
acids, 38 kDa), HNRNPA2 (341 amino acids, 36 kDa),
HNRNPB1b (313 amino acids, 33 kDa), and HNRNPA2b
(301 amino acids, 31 kDa) (He and Smith, 2009; Han et
al., 2010). In addition, a large number of pseudogenes of
the two genes are distributed throughout the genome. In
cells from different tissues, HNRNPA1a and HNRNPA2
are the main executors of HNRNPA1 and HNRNPA2

gene function, as they are expressed at much higher levels
compared to the other transcripts.
HNRNPA1 and HNRNPA2 share a similar structure
composed of two RNA recognition motifs (RRMs) and
one glycine-rich domain (GRD). The RRM-glycine series
structure can bind to nucleic acids and proteins, and thus
participates in multiple levels of nucleic acid metabolism
and transport, including alternative splicing (Mayeda et
al., 1994; Martinez-Contreras et al., 2007), RNA stability
(Fahling et al., 2006; Zhao et al., 2009), RNA transport
(Rebane et al., 2004; Carson and Barbarese, 2005), telomere
repair (Moran-Jones et al., 2005; Zhang et al., 2006), and
transcription and translation regulation (Campillos et
al., 2003; Zhao et al., 2008; Lin et al., 2009). Embryos of
homozygous mice in which HNRNPA1 has been knocked
out do not survive, whereas the embryos of heterozygous
mice exhibit numerous changes with alternative splicing
and gene expression accompanied by severe muscular
development defects, suggesting that HNRNPA1 play
indispensable roles in the development process (Liu et al.,
2017).
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HNRNPA1 and HNRNPA2 have also been associated
with the occurrence of many human diseases. In particular,
they are abnormally expressed in various types of tumors
such as small cell lung cancer and gastric cancer (RomeroGarcia et al., 2014; Chen et al., 2018), and knockdown of
HNRNPA1 or the use of adapters targeting HNRNPA2
can inhibit cancer cell proliferation, suggesting potential
targets for cancer treatment (Li et al., 2015; Liu et al.,
2016). Genetic studies have shown that a single amino
acid mutation in the GRD domain of HNRNPA1 and
HNRNPA2 protein is related to the proteinopathy of
multiple systems and amyotrophic lateral sclerosis (Kim et
al., 2013). In addition, HNRNPA1 and HNRNPA2 play an
important role in RNA metabolism, which is consistently
dysregulated in neurodegenerative diseases. Indeed,
changes of HNRNPA1 and HNRNPA2 expression can
improve the condition of patients with amyotrophic lateral
sclerosis, spinal muscular atrophy, Alzheimer’s disease, and
other neurodegenerative diseases (Bekenstein and Soreq,
2013). Therefore, exploring the mechanism underlying the
expression regulation of HNRNPA1 and HNRNPA2 may
improve the understanding of these vital cellular processes
and diseases. Toward this end, in the present study, we
evaluated the compensatory expression and regulation of
HNRNPA1 and HNRNPA2, and performed preliminary
exploration of the molecular mechanism.
2. Materials and methods
2.1. Protein structural analysis and sequence alignment
The family and domains options in the UniProt database1
were used for protein structure analysis. The full-length
transcripts of HNRNPA1b (NM_031157.3, NP_112420.1)
and HNRNPA2 (NM_031243.2, NP_112533.1) were
obtained from the National Center of Biotechnology
Information, and the HNRNPA1 and HNRNPA2 protein
sequences were aligned with Clustal Omega.2
2.2. Plasmid construction and siRNAs
For overexpression, the previously generated plasmids
pCGT7-HNRNPA1 and pCGT7-HNRNPA2 containing
an N-terminal T7-tag (T7-A1 and T7-A2, respectively),
referenced by (Hua et al., 2008). PGL3-A1/2 was
constructed from two fragments: a 1084-bp fragment of
the A1 promoter containing 1078 bases upstream of the
start codon and the first two amino acids, and a 1323bp fragment of the A2 promoter containing 1317 bases
upstream of the start codon and the first two amino
acids. These fragments were cloned into PGL3-basic
vector (Promega, Madison, WI, USA) using Mlu I and
Xho I digestion sites. To generate plasmid pmiR-A1/2,
Sal I and Not I restriction sites were added to both ends

1
UniProt Consortium (2021). UniProt database [online]. Website
https://www.uniprot.org/ [accessed 00 Month Year].
2
EMBL-EBI (2021). Clustal Omega [online]. Website https://www.
ebi.ac.uk/Tools/msa/clustalo/ [accessed 00 Month Year].
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of the HNRNPA1 and HNRNPA2 3′UTR, and subcloned
into the Xho I/Not I sites of the pmiR-RB-Reporter vector
(RiboBio, Guangzhou, China). Restriction endonucleases
were purchased from New England Biolabs (Beverly,
MA, USA). Primer pairs used for cloning are listed in
supplementary table. All siRNAs were purchased from
Genepharma (Shanghai, China), and their sequences are
given in Table S1.
2.3. Cell culture and transfection
HEK293 cells (Cell Bank, Chinese Academy of Sciences,
Shanghai, China) were cultured in Dulbecco’s modified
Eagle’s medium (Invitrogen, Thermo Fisher Scientific,
Waltham, MA, USA), supplemented with 10% (v/v) fetal
bovine serum (Gibco, Thermo Fisher Scientific), 100 U/
mL penicillin, and 100 μg/mL streptomycin (Beyotime
Biotechnology, Shanghai, China) at 37 °C in a humidified
5% CO2 atmosphere. Cells in the logarithmic growth phase
were seeded in a 6-well plate at a density of 105 cells/well. The
next day, 1 μg of plasmid or 100 nM siRNA was delivered
to the cells using Lipofectamine 2000 (Life Technologies,
Carlsbad, CA, USA) following the manufacturer
instructions. RNAs and proteins were extracted at 48 h
after transfection. The influence of each siRNA or plasmid
on the expression of HNRNPA1 and HNRNPA2 at the
mRNA and protein level was then detected by reverse
transcription-quantitative polymerase chain reaction (RTqPCR) and Western blotting, respectively.
2.4. Reverse transcription-polymerase chain reaction
(RT-PCR)
Total RNA was extracted from the transfected cells using
TRIzol reagent (Life Technologies), and 1 μg of each
RNA sample was used in a 20-μl reaction for first-strand
cDNA synthesis with oligo (dT)18 and M-MLV reverse
transcriptase (HiScript II Q Select RT SuperMix, Vazyme
Biotech, Nanjing, China). The products were amplified
semiquantitatively using 28 cycles (95 °C for 15 s, 58 °C
for 15 s, 72 °C for 40 s) with a series of primers (Table
S2). PCR products were separated by agarose gels, and
transcripts were quantified using ChamQ Universal SYBR
qPCR Master Mix kit (Vazyme Biotech) on an ABI 7500
fluorescent quantitative PCR instrument using genespecific primers (Table S3) according to the manufacturer
instructions.
2.5. Western blotting
The transfected cells were harvested in lysis buffer
(Beyotime Biotechnology) to obtain the total protein.
Protein samples were separated by 10% SDS-PAGE and
electroblotted onto polyvinylidene fluoride membranes
(Millipore, Burlington, MA, USA). The membranes were
blocked for 2 h with 5% (w/v) nonfat milk. The blots
were then probed with monoclonal antibodies (anti-T7
antibody, Sigma-Aldrich, St. Louis, MO, USA; anti-βtubulin antibody, Santa Cruz Biotechnology, Dallas, TX,
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USA; 1:1000 dilution) or polyclonal antibodies (antiHNRNPA1 antibody, Proteintech, Rosemont, IL, USA;
anti-HNRNPA2 antibody, Proteintech, 1:1000 dilution)
overnight at 4 °C followed by incubation with secondary
IRDye 680RD goat antimouse or goat antirabbit antibody
(LI-COR Biosciences, Lincoln, NE, USA; 1:2000 dilution).
Protein signals were detected with an Odyssey Infrared
Imaging System (LI-COR Biosciences). ImageJ software
was used for gray intensity analysis.
2.6. Dual-luciferase reporter assay
The pmiR-RB-Report vector was used as a dual-luciferase
reporter plasmid. Since the PGL3 vector only has the
firefly luciferase report gene, the pRL-TK plasmid (Promega)
was used as a transfection control and cotransfected with
PGL3. The transfected cells were washed with phosphatebuffered saline and the fluorescence activity was detected
using a luciferase analysis kit (Promega). In brief, the cells
were lysed with 1× PLB lysate, and 15 μL of the PLB lysate
supernatant was added to each well of a new 96-well optical
plate, mixed with 100 μL LAR II containing luciferase, and
then 100 μL Stop & Glo reagent was added for detection
of the luminescence intensity of Renilla luciferase, and
corresponding ratios were calculated.

2.7. Statistical analysis
SPSS17.0 was used for statistical analyses (SPSS Inc.,
Chicago, IL, USA). Student’s t-test was used to analyze
the differences between two groups, and the data are
presented as the mean ± SEM; p < 0.05 was considered
statistically significant. GraphPad Prism was used to draw
the bar chart.
3. Results
3.1. High homology between HNRNPA1 and HNRNPA2
The publicly available full-length HNRNPA1 and
HNRNPA2 amino acid sequences were retrieved and
compared. Both proteins contain three domains: RRM1,
RRM2, and GRD (Figure 1A). Sequence alignment
showed that overall amino acid sequence homology
of 64% (238/372), with 78% (65/83) homology for the
RRM1 domain, 86% (68/79) for the RRM2 domain, and
61% (92/151) for the GRD domain (Figure 1B). Peptide
sequences comparison indicated that HNRNPA1 and
HNRNPA2 are highly homologous, and the higher
homology in their RRM domains suggests similar
functions in regulating RNA metabolism.
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Figure 1. High homology of HNRNPA1 and HNRNPA2. (A) HNRNPA1 and HNRNPA2 primary sequence of the peptides. The number
represents the location of amino acids, and the gray area represents the location of functional domains. (B) Amino acid sequence
alignment of HNRNPA1 and HNRNPA2. * indicates an identical amino acid at that site.
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3.2. HNRNPA1 and HNRNPA2 are paralogs that
compensatory regulate each other’s expression
RT-qPCR data showed that HNRNPA1 siRNA caused a
65% decrease in the HNRNPA1 expression level compared
with NC siRNA, but upregulated the mRNA level of
HNRNPA2 by 0.55-fold (Figure 2A). Similarly, HNRNPA2
siRNA caused a 71% reduction in the level of HNRNPA2
expression, but upregulated HNRNPA1 expression by
0.73-fold. Simultaneous transfection of HNRNPA1 siRNA
and HNRNPA2 siRNA resulted in a 52% and 62% decrease
of HNRNPA1 and HNRNPA2 expression, respectively,
showing less effective silencing than transfection with a
single siRNA. Western blotting showed consistent results
at the protein level as observed with qPCR at the mRNA
level. The HNRNPA1 or HNRNPA2 protein level was
effectively knocked down, and a significant increase of
HNRNPA1 or HNRNPA2 expression was observed (0.34fold and 0.56-fold increase, respectively) (Figure 2B).
In addition, overexpression of HNRNPA1 and
HNRNPA2 markedly decreased the mRNA level of
HNRNPA2 and HNRNPA1, respectively (Figure 2C).
Western blotting showed consistent results, with a 0.9fold increase in the protein expression of HNRNPA1 after
transfection of the T7-A1 plasmid, whereas the level of
HNRNPA2 protein was decreased by 52%. Similarly, the
T7-A2 plasmid increased the HNRNPA2 expression level
by 0.6-fold and caused a 41% reduction of the HNRNPA1
expression level (Figure 2D).
These results suggested the compensatory regulation
of expression between HNRNPA1 and HNRNPA2.
Further, the consistency between the RT-qPCR and
Western blotting results showed that changes in the two
genes were consistent at the mRNA and protein levels,
suggesting that the compensatory regulation occurred at
the transcriptional or posttranscriptional process of gene
expression rather than at the translation level.
Regulating gene expression in eukaryotes generally
includes three levels: transcription, posttranscription
(alternative splicing, RNA stability, etc.), and translation. In
the following, we discuss the mechanism of compensatory
regulation from three levels of alternative splicing, RNA
stability, and translation.
3.3. Compensatory regulation of HNRNPA1 and
HNRNPA2 is not mediated by alternative splicing
The most common function of HNRNPA1 and HNRNPA2
is in the regulation of alternative splicing. It has been
reported that HNRNPA1 regulates its own expression by
inhibition of intron 10 splicing of HNRNPA1 pre-mRNA
(Suzuki and Matsuoka, 2017). Therefore, we hypothesized
that the compensatory regulation between HNRNPA1 and
HNRNPA2 may be mediated by alternative splicing. To
test this hypothesis, several primers were used to examine
alternative splicing by the endogenous HNRNPA1 and
HNRNPA2 gene in HEK293 cells that cover all exons of the
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two genes. Using the cells transfected with pCGT7 empty
vector as a control, overexpression of HNRNPA1 with T7A1 plasmid did not substantially affect alternative splicing
except for a slight difference in exon splicing of Exon 7
and Exon 10 on HNRNPA2 (Figure 3A). Overexpression
of HNRNPA2 with T7-A2 plasmid did not significantly
alter the alternative splicing of HNRNPA1 (Figure 3B).
These results suggested that alternative splicing is not the
main cause of the compensatory expression regulation of
HNRNPA1 and HNRNPA2. Interestingly, overexpression
of HNRNPA1 or HNRNPA2 decreased the production
of each primer pair compared with the control group,
supporting that the hypothesis of the compensatory
regulation was the change in total RNA rather than a
change in alternative splicing of some exons or introns.
3.4. Compensatory regulation of HNRNPA1 and
HNRNPA2 is mediated by their 3′UTRs
Regulation mechanisms at the RNA level include
transcription, splicing, and RNA stability. Two luciferase
reporters were used to test molecular mechanism of
compensatory regulation with respect to transcription and
RNA stability. The HNRNPA1 and HNRNPA2 promoter
region was cloned into the PGL3 vector to construct the
reporter plasmid PGL3-A1/A2, and the HNRNPA1 and
HNRNPA2 3′UTR sequence was cloned into the vector
pmiR-RB-Report to construct the plasmid pmiR-A1/
A2 (Figure 4A). The luciferase reporter plasmids were
then cotransfected with the T7 empty control vector or
T7-A1/A2 plasmid, and luciferase activity in each group
was detected 48 h posttransfection. Overexpression of
HNRNPA1 did not affect luciferase activity of pmiR-A2
(HNRNPA2 promoter) but significantly inhibited the
luciferase activity of PGL3-A2 (HNRNPA2 3′UTR) (Figure
4B). For the impact of HNRNPA2 protein on HNRNPA1
expression, the results showed that overexpression of
HNRNPA2 did not affect luciferase activity of pmiR-A1
(HNRNPA1 promoter) but significantly inhibited the
luciferase activity of PGL3-A1 (HNRNPA1 3′UTR)
(Figure 4C). These results suggested that the compensatory
regulation of HNRNPA1 and HNRNPA2 was mediated by
their 3′UTRs rather than by their promoters.
3.5. Compensatory regulation of HNRNPA1 and
HNRNPA2 is inhibited by cycloheximide
Cycloheximide (CHX) is a compound that inhibits the
protein biosynthesis process of eukaryotes and is also an
inhibitor of nonsense-mediated RNA decay (NMD). We
next tested whether CHX plays a role in compensatory
regulation of HNRNPA1 and HNRNPA2. The HEK 293
cells were treated with 75 μM CHX after 30 h transfection
of siRNA, and HNRNPA1 and HNRNPA2 expression was
detected by Western blotting 18 h after CHX treatment.
Knockdown of HNRNPA1 and HNRNPA2 did not
significantly increase the expression of HNRNPA2/A1
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Figure 2. HNRNPA1 and HNRNPA2 are paralogs that compensate for each other’s expression. (A and C) Histograms showing the
mRNA levels of HNRNPA1 and HNRNPA2 analyzed by RT-qPCR; data were normalized to the level of GAPDH. (B and D) Protein
levels of HNRNPA1 and HNRNPA2 analyzed by Western blot; data were normalized to β-tubulin. The statistical results from three
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in cells treated with CHX compared with the no-CHX
group (Figures 5A and 5B). These results suggest that
compensatory regulation of HNRNPA1 and HNRNPA2 is
inhibited by CHX, the mechanism may be the inhibition
of extensive protein synthesis or NMD.
4. Discussion
A disorder in gene expression can result in disease
development; thus, gene expression is regulated at
several levels through many mechanisms, including

the transcription, posttranscription, translation, and
posttranslation levels. HNRNPA1 and HNRNPA2, as
abundant RNA-binding proteins are well-known to widely
regulate gene expression; however, the mechanisms by
which their own expression is regulated have thus far
remained unclear. Here, we reported the compensatory
regulation of HNRNPA1 and HNRNPA2, and confirmed
that they are mediated by their respective 3′UTRs.
There are numerous pseudogenes of HNRNPA1 and
HNRNPA2 distributed throughout the genome. Although
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we strictly paid attention to the specificity of primers
during the experiment, we ignored the influence of
pseudogene expression mRNA on the results of RT-PCR
and real time PCR. Fortunately, the experiment results
of western blot and luciferase reporters were not affected
by this. Therefore, the existence of pseudogenes does not
affect our key conclusions.
Wang et al. (2017) reported a degradation mechanism
of HNRNPA1 in which epidermal growth factor promoted
its degradation by activating ubiquitin signaling. In the
present study, we found that the change in the protein
expression of HNRNPA1 and HNRNPA2 was consistent
with that of its mRNA, suggesting expression regulation
by more than one mechanism. Indeed, the cooperation
of multiple mechanisms ensures that the gene expression
regulation of eukaryotes is complex and precise.
Overexpression of several RNA-binding proteins has
been reported to provide feedback to regulate their own
expression through self-regulation (Sun et al., 2010; Dai

et al., 2012; Suzuki and Matsuoka, 2017); however, selfregulation pathway does not apply to all RNA binding
proteins. To our knowledge, the compensatory regulation
of homologous RNA-binding proteins has not been
reported until now.
Sun et al. (2010) reported the self-regulation
mechanisms of SRSF1, a member of the arginine
serine family. At the posttranscriptional level, SRSF1
overexpression regulated the alternative splicing of its own
endogenous genes and induced the production of new
unstable transcripts, which were then degraded by the
NMD pathway through its 3′UTR. At the translation level,
SRSF1 overexpression altered the distribution of its mRNA
by inducing the transformation to a monosome, thus
inhibiting RNA translation. Although these RNA-binding
proteins also exhibit self-regulation, the mechanisms are
quite different to that identified for HNRNPA1. Suzuki
and Matsuoka (2017) reported the autoregulation of
HNRNPA1 as exogenous overexpression of HNRNPA1
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downregulated the expression of endogenous HNRNPA1.
In this case, the autoregulation of HNRNPA1 neither
depended on its 3′UTR nor occurred through the NMD
pathway, but was rather caused by inhibition of the
splicing of intron 10 in endogenous pre-mRNA mediated
by HNRNPA1 itself. However, in this study, we did not
detect a change of alternative splicing of HNRNPA1 intron
10 caused by HNRNPA2 overexpression. Alternatively, we
found that the compensatory regulation of HNRNPA1
and HNRNPA2 expression involved the 3′UTR. This
differs from the self-regulation mechanism of HNRNPA1,
indicating that HNRNPA1 and HNRNPA2 expression are
controlled by complex and diverse mechanisms.
The detailed molecular mechanism by which
HNRNPA1 and HNRNPA2 proteins activate the
HNRNPA1 and HNRNPA2 mRNA NMD pathway requires
further examination. The termination codon of both genes
is located in the penultimate exon. Regions downstream of
the termination codon contain the exon junction complex,
which can stimulate the rapid deadenylation of mRNA and
degrade mRNA by the CCR4-Not complex. Geissler et al.
(2016) reported that UAASUAUU, a conserved sequence
in the 3′UTR, is widely involved in RNA degradation,
which can bind to HNRNPA1 and HNRNPA2 to recruit
the CCR4-Not complex, thereby initiating target RNA
degradation. Although bioinformatics analysis showed
that the optimal binding sequence of HNRNPA1 and
HNRNPA2 protein was UAGGGU/A (Burd and Dreyfuss,
1994; Bruun et al., 2016), the high abundance of these
proteins in cells may enable binding to other sequences.
The 3′UTRs of HNRNPA1 and HNRNPA2 contain
multiple SUUAU motifs reported by Geissler et al. (2016)
and the optimal UAGG motif. Therefore, the mechanism
of HNRNPA1 and HNRNPA2 compensatory regulation
may involve direct binding of HNRNPA1 and HNRNPA2
to the HNRNPA1 and HNRNPA2 mRNA 3′UTR to
promote the recruitment of the CCR4-Not complex after
NMD activation. When the HNRNPA1 and HNRNPA2
protein concentration changes, the number of CCR4Not complexes recruited by HNRNPA1 and HNRNPA2

protein will change accordingly, altering the degradation
rate of mRNA and enabling compensatory regulation.
HNRNPA1 and HNRNPA2 have very similar functions,
and few studies have directly demonstrated their functional
differences. Therefore, further investigation is warranted to
determine why cells would spend the energy to express two
proteins with the same functions at such high levels. The
compensatory regulation phenomenon found in this study
is similar to the widely observed genetic compensation
phenomenon as a common fault tolerant mechanism in
eukaryotes. When a gene is mutated or deleted, a series of
reactions occur to improve the expression of other similar
genes in its family, thus compensating for the function of
the inactivated gene. Because HNRNPA1 and HNRNPA2
play such a crucial role in regulating gene expression, its
abnormal expression can cause numerous downstream
gene expression changes. Through compensatory
regulation, HNRNPA1 and HNRNPA2 expression can
be buffered in a complex and changeable environment to
ensure the normal progression of various life activities.
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Supplementary tables
Table S1. Primers for cloning luciferase report vector.
Names or
products
A1 promotor
A2 promotor
A1 3′UTR
A2 3′UTR

Forward primer (from 5′ to 3′)

Reverse primer (from 5′ to 3′)

acacgcgtTCTCCCACATTCCGATGGCC
atctcgagAGACATGACGGCAGGGTG
acacgcgtACGCGTGTGGCATCTGAAGCAC
atctcgagCTCCATCGCGGACTCAGTCG
acgtcgacTAATTAGGAAACAAAGCTTAGCAGG acgcggccgcTTCAAGAGAATTAAATCGTTTATTG
acgtcgacTGAGCTTCTTCCTATTTGCC
acgcggccgcTCCTTTAGAATTATTTTATTAAATCATAAATG
Table S2. Primers for detecting gene mRNA level.
Gene name
HNRNPA1
HNRNPA2
GAPDH

Forward primer (from 5′ to 3′)
TCAGAGTCTCCTAAAGAGCCC
AGCTTTGAAACCACAGAAGAA
TCAACGACCACTTTGTCAAGCTCA

Reverse primer (from 5′ to 3′)
ACCTTGTGTGGCCTTGCAT
TTGATCTTTTGCTTGCAGGA
GCTGGTGGTCCAGGGGTCTTACT

Table S3. Sequences of siRNAs used to knock down
HNRNPA1 and HNRNPA2 and NC siRNA.
Gene
HNRNPA1 siRNA
HNRNPA2 siRNA
NC siRNA

Sense (from 5′ to 3′)
CAGCUGAGGAAGCUCUUCA
GGAACAGUUCCGUAAGCUC
UUCUCCGAACGUGUCACGU

Table S4. Primers for RT-PCR to examine HNRNPA1 and HNRNPA2
alternative splicing.
Name

Primer (from 5′ to 3′)
F- ACTGAGTCCGCGATGGAG
A2 E1-E5
R-AGTATCTTCTTTAATTCCG
F- ACTGAGTCCGCGATGGAG
A2 E1-E4
R- TTGATCTTTTGCTTGCAGGA
F- AGCTTTGAAACCACAGAAGAA
A2 E3-E7
R- AGATCCTCCTCTAAAGTTACTTC
F- AGAAATACCATACCATCAATGG
A2 E6-E9
R- TCCTCCATAGTTGTCATAACCA
F- AGG CAA CTT TGG CTT TGG
A2 E7-E10
R-CTCCACCATATGGTCCC
F- TGGTTATGACAACTATGGAGGAG
A2 E9-E12
R- ACTGCATATTTATGCATGACTG
F- TGGTTATGACAACTATGGAGGAG
A2 E9-E12-2
R-ACAGTAAGGTAATGTTATTAAATAATCC
F- CCGTCATGTCTAAGTCAGAG
A1 E1-E4
R- CTTCAGTGTCTTCTTTAATGCC
F- CCAGAGAAGATTCTCAAAGACC
A1 E3-E7
R- TCCATTATAGCCATCCCCAC
F- ACTTTGGTGGTGGTCGTGG
A1 E6-E9
R-TACTGCTGCTGCTGGAACC
F- AGCTGAGGAAGCTCTTCATTG
A1 E2-E6
R-ACCGAAACCACCTCCACG
F- AGGTGGTGGAAGCTACAATGATTTTG
A1 E8-E10
R- AGTCACAAATACAGTCCTCGAG

Size (bp)
346
160
609
362
269/389
343
424
358
467
336
600
381
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